NYSE - Delayed Quote USD

Glaukos Corporation (GKOS)

100.11 -0.82 (-0.81%)
At close: April 25 at 4:00 PM EDT
100.11 0.00 (0.00%)
After hours: April 25 at 5:05 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Thomas William Burns Chairman & CEO 774.9k 24.98M 1961
Mr. Joseph E. Gilliam President & COO 1.18M 4.01M 1976
Mr. Alex R. Thurman Senior VP & CFO 621.24k -- 1970
Dr. Tomas Navratil Ph.D. Chief Development Officer 866.18k -- 1977
Dr. Mory Gharib Ph.D. Co-Founder -- -- --
Mr. Christopher William Lewis Vice President of Investor Relations & Corporate Affairs -- -- --
Ms. Diana A. Scherer VP of Compliance & Deputy General Counsel -- -- --
Ms. Michele M. Allegretto Senior Vice President of Human Resources -- -- --
Mr. Chris M. Calcaterra Executive Vice President of Global Commercial Operations 198.66k -- 1960
Ms. Jane E. Rady Senior Vice President of Corporate Strategy & Business Development -- -- 1948

Glaukos Corporation

One Glaukos Way
Aliso Viejo, CA 92656
United States
949 367 9600 https://www.glaukos.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
907

Description

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Corporate Governance

Glaukos Corporation’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024
Glaukos Corporation Earnings Call

Related Tickers

RXST RxSight, Inc.
51.89
-1.80%
 
SGHT Sight Sciences, Inc.
5.14
-8.54%
 
ITGR Integer Holdings Corporation
111.15
-9.83%
 
LIVN LivaNova PLC
55.10
-1.50%
 
PRCT PROCEPT BioRobotics Corporation
52.28
-0.38%
 
IRTC iRhythm Technologies, Inc.
111.27
-4.43%
 
AXNX Axonics, Inc.
66.54
-0.15%
 
NVRO Nevro Corp.
11.62
-7.11%
 
BRKR Bruker Corporation
80.59
-1.96%
 
SNN Smith & Nephew plc
23.88
-2.81%